NEW YORK, April 6, 2017 /PRNewswire/ --
Today's research on Stock-Callers.com brings investors' attention back tothe Medical Instruments and Supplies industry, which is engaged in the research, development, and production of non-electronic medical, surgical, dental, and veterinary instruments. Four equities have been selected for coverage this morning and they
On Wednesday, shares in Bethlehem, Pennsylvania-based OraSure Technologies Inc. recorded a trading volume of 1.01 million shares, which was above their three months average volume of 887,980 shares. The stock ended the session 2.14% lower at $12.36. The Company's shares have gained 7.01% in the last one month, 38.26% over the previous three months, and 40.77% on an YTD basis. The stock is trading 13.67% above its 50-day moving average and 43.57% above its 200-day moving average. Moreover, shares of OraSure Technologies, which together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the US, Europe, and internationally, have a Relative Strength Index (RSI) of 61.78. The free research report on OSUR is available at:
Morrisville, North Carolina headquartered TransEnterix Inc.'s stock closed the day 5.31% lower at $1.07. A total volume of 825,331 shares was traded, which was above their three months average volume of 626,240 shares. The Company's shares are trading 16.94% below their 50-day moving average. Additionally, shares of TransEnterix, which focuses on the development and commercialization of surgical robotic systems, have an RSI of 36.33.
On March 22nd, 2017, TransEnterix announced that it has expanded the clinical adoption of the Senhance Robotic Surgical System to include a full range of hernia repair surgeries. The complimentary report on TRXC can be downloaded at:
Shares in San Clemente, California headquartered Glaukos Corp. recorded a trading volume of 396,642 shares. The stock ended yesterday's trading session 2.98% lower at $50.45. The Company's shares have advanced 14.48% in the past month, 47.51% in the previous three months, and 47.08% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 10.54% and 37.49%, respectively. Furthermore, shares of Glaukos, which focuses on the development and commercialization of products and procedures designed to treat glaucoma, have an RSI of 59.55.
On March 16th, 2017, Glaukos announced that the Current Procedural Terminology Editorial Panel of the American Medical Association has granted five-year extensions to three Category III CPT codes that describe insertion of aqueous drainage devices into the anterior chamber of the eye using Micro-Invasive Glaucoma Surgery. Visit us today and download our complete research report on GKOS for free at:
San Diego, California headquartered Tandem Diabetes Care Inc.'s stock finished Wednesday's session 8.00% lower at $1.15. A total volume of 727,343 shares was traded, which was above their three months average volume of 528,800 shares. The Company's shares are trading below their 50-day moving average by 45.12%. Additionally, shares of Tandem Diabetes Care, which designs, develops, and commercializes various products for people with insulin-dependent diabetes in the US, have an RSI of 26.54.
On March 08th, 2017, Tandem Diabetes Care announced plans to implement a new infusion set connector for Tandem insulin pump cartridges and infusion sets - the t:lock™ Connector. The new design reduces the time required to fill the infusion set tubing by approximately 30 seconds and reduces the amount of insulin used in the process by approximately four and a half units.
On March 30th, 2017, research firm Piper Jaffray resumed its 'Neutral' rating on the Company's stock. Get free access to your technical report on TNDM at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Nocturnal polyuria refers to increased urine output during night, without an associated increase in ...
Nootropics are drugs or substances which improve cognition that are being increasingly used ...
Pterygium or Surfer's eye is described as a proliferative disorder of the ocular surface possibly ...View All